Back

GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences

20 May 2025 (10:10 - 10:19)
Organised by: Logo
Congress Presentation Part of: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis
Doctor N. Sari (Jakarta, ID)
Abstract Slides Video
Presentation thumbnail
The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors
Doctor M. Laufer-Perl (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus
Doctor M. Gvili Perelman (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Evaluation of vascular cell adhesion molecule-1 (VCAM-1) level changes in patients with lymphoproliferative diseases during antitumor therapy
Doctor R. Alieva (Tashkent, UZ)
Abstract Slides Video

Access the full session

Session thumbnail
Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies
Video

The Event

Event poster

Heart Failure 2025

20 May 2025 10:10 CET
You may be interested in
thumbnail
Congress Presentation
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
thumbnail
Congress Presentation
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
thumbnail
Congress Presentation
The GLP1RA Semaglutide exerts significant cardioprotective properties against anthracycline+/-trastuzumab induced cardiotoxicity: biochemical evidences

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources